Skip to main content
SpringerLink
Log in

Management and Prevention of Diabetic Complications

  • Chapter
  • First Online:
Atlas of Diabetes

Abstract

Type 2 diabetes is a chronic disease characterized by insulin resistance, impaired insulin secretion, and hyperglycemia. The long-term complications of diabetic retinopathy, nephropathy, neuropathy, and accelerated atherosclerosis lead to significant morbidity in the form of preventable blindness, end-stage renal disease (ESRD), limb amputations, and premature cardiovascular disease (CVD) [1]. Although patients with diabetes suffer from the morbidity of their microvascular complications, the majority of them ultimately die from the complications of macrovascular coronary artery disease (CAD).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. http://diabetes.niddk.nih.gov/DM/PUBS/statistics/ Accessed September 5, 2009.

    Google Scholar 

  2. De Fronzo RA: Lilly Lecture 1987: The triumvirate: β cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667–687.

    Google Scholar 

  3. Pratley RE, Weyer C: The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001, 44:929–945.

    Article  PubMed  CAS  Google Scholar 

  4. Reaven GM: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005, 47:201–210.

    PubMed  CAS  Google Scholar 

  5. Fagan TC, Deedwania PC: The cardiovascular dysmetabolic syndrome. Am J Med 1998, 105:77 S–82 S.

    Article  PubMed  CAS  Google Scholar 

  6. Wilson PW, D’Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066–3072.

    Article  PubMed  CAS  Google Scholar 

  7. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615–1625.

    Article  PubMed  CAS  Google Scholar 

  8. Brownlee M: Biochemistry and molecular cell biology of ­diabetic complications. Nature 2001, 414:813–820.

    Article  PubMed  CAS  Google Scholar 

  9. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837–853.

    Article  Google Scholar 

  10. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854–865.

    Article  Google Scholar 

  11. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 7160:703–713.

    Article  Google Scholar 

  12. Buse JB, Ginsberg HN, Bakris GL, et al.: American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114–126.

    Google Scholar 

  13. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  Google Scholar 

  14. Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, et al.  : How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diabet Med 2008, 25:1433–1439.

    Article  PubMed  CAS  Google Scholar 

  15. Fong DS, Aiello LP, Ferris FL 3 rd, et al.: Diabetic retinopathy. Diabetes Care 2004, 27:2540–2553..

    Google Scholar 

  16. American Diabetes Association: Position statement: diabetic retinopathy. Diabetes Care 2004, 27:S84–S87.

    Article  Google Scholar 

  17. Gordois A, Scuffham P, Shearer A, Oglesby A: The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complicat 2004, 18:18–26.

    Article  PubMed  Google Scholar 

  18. American Diabetes Association: Position statement: diabetic nephropathy. Diabetes Care 2004, 27:S79–S83.

    Article  Google Scholar 

  19. American Diabetes Association: Clinical practice recommendations 2009. Diabetes Care 2011, 34:1–61.

    Article  Google Scholar 

  20. Friedman E: Renal syndromes in diabetes. Endocrinol Metab Clin North Am 1996, 25:293–324.

    Article  PubMed  CAS  Google Scholar 

  21. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.

    Article  Google Scholar 

  22. Harati Y: Diabetic neuropathies: unanswered questions. Neurol Clin 2007, 25:303–317.

    Google Scholar 

  23. Vinik A, Ullal J, Parson HK, et al.: Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2006, 2:269–281.

    Article  PubMed  CAS  Google Scholar 

  24. Frykberg RG, Zgonis T, Armstrong DG, et al.: Diabetic foot ­disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2000, 39(Suppl 5):S1–S60.

    Google Scholar 

  25. American Diabetes Association: Position statement: preventive foot care in diabetes. Diabetes Care 2004, 27:S63–S64.

    Article  Google Scholar 

  26. Hidalgo-Tamola J, Chitaley K: Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2009, 6:916–926.

    Article  PubMed  CAS  Google Scholar 

  27. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.

    Google Scholar 

  28. ADVANCE Collaborative Group, Patel A, MacMahon S, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.

    Google Scholar 

  29. Duckworth W, Abraira C, Moritz T, et al.: VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139.

    Google Scholar 

  30. American Diabetes Association: Position statement: management of dyslipidemia in adults with diabetes mellitus. Diabetes Care 2004, 27:S68–S71.

    Article  Google Scholar 

  31. American Diabetes Association: Position statement: aspirin therapy in diabetes. Diabetes Care 2004, 27:S72–S73.

    Article  Google Scholar 

  32. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.

    Article  PubMed  Google Scholar 

  33. Eastman RC, Javitt JC, Herman WH, et al.: Model of complications in NIDDM: Analysis of the health benefits and cost-­effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997, 20:735–744.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine, Endocrinology, and Diabetes, VA San Diego Healthcare System, San Diego, CA, USA

    Sunder Mudaliar MD, FRCP, FACP, FACE (Clinical Professor of Medicine) & Robert R. Henry MD (Professor of Medicine/Chief)

Authors
  1. Sunder Mudaliar MD, FRCP, FACP, FACE
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert R. Henry MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunder Mudaliar MD, FRCP, FACP, FACE .

Editor information

Editors and Affiliations

  1. Division of Endocrinology,, Diabetes & Metabolism, University of Miami, Miami, 33136, Florida, USA

    Jay Skyler

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Mudaliar, S., Henry, R.R. (2012). Management and Prevention of Diabetic Complications. In: Skyler, J. (eds) Atlas of Diabetes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-1028-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1028-7_11

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-1027-0

  • Online ISBN: 978-1-4614-1028-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation